- Home
- IOVA vs NMM Comparison
IOVA vs NMM Comparison
Compare IOVA & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NMM
- Stock Information
- Founded
- IOVA 2007
- NMM 2007
- Country
- IOVA United States
- NMM Greece
- Employees
- IOVA N/A
- NMM N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NMM Marine Transportation
- Sector
- IOVA Health Care
- NMM Consumer Discretionary
- Exchange
- IOVA Nasdaq
- NMM Nasdaq
- Market Cap
- IOVA 1.0B
- NMM 959.8M
- IPO Year
- IOVA N/A
- NMM 2007
- Fundamental
- Price
- IOVA $3.17
- NMM $36.91
- Analyst Decision
- IOVA Strong Buy
- NMM Strong Buy
- Analyst Count
- IOVA 9
- NMM 1
- Target Price
- IOVA $18.22
- NMM $80.00
- AVG Volume (30 Days)
- IOVA 9.3M
- NMM 123.2K
- Earning Date
- IOVA 05-08-2025
- NMM 05-07-2025
- Dividend Yield
- IOVA N/A
- NMM 0.55%
- EPS Growth
- IOVA N/A
- NMM N/A
- EPS
- IOVA N/A
- NMM 11.07
- Revenue
- IOVA $164,070,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- IOVA $182.20
- NMM N/A
- Revenue Next Year
- IOVA $62.10
- NMM $6.96
- P/E Ratio
- IOVA N/A
- NMM $3.25
- Revenue Growth
- IOVA 13698.99
- NMM 0.28
- 52 Week Low
- IOVA $2.70
- NMM $28.37
- 52 Week High
- IOVA $13.60
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- IOVA 43.38
- NMM 59.57
- Support Level
- IOVA $3.02
- NMM $35.03
- Resistance Level
- IOVA $3.73
- NMM $37.10
- Average True Range (ATR)
- IOVA 0.25
- NMM 1.22
- MACD
- IOVA 0.01
- NMM 0.63
- Stochastic Oscillator
- IOVA 25.33
- NMM 92.13
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.